

**Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development (Biologics, Vaccines, Cell & Gene Therapy), Research, Biopharma Production) & Region - Global Forecast to 2028**

Market Report | 2024-02-05 | 408 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The global recombinant proteins market size is projected to reach USD 3.2 billion by 2028 from USD 2.2 billion in 2023, at a CAGR of 7.2% during the forecast period. Factors such as rising demand for biologics & biosimilars due to patent expiry, increasing prevalence of chronic diseases, increased government support for life sciences research & development and growing preference for personalized medicine..

"The growth factors and chemokines segment held the dominant share in the recombinant proteins market"

Based on product, the global recombinant proteins market is segmented into growth factors and chemokines, kinase proteins, membrane proteins, immune response proteins, structural proteins, regulatory proteins, recombinant metabolic enzymes, adhesion molecules and receptors, and other recombinant proteins. The growth factors and chemokines segment is further segmented into interferons, interleukins and other growth factor & chemokines. The growth factors and chemokines segment is anticipated to grow at significant CAGR due to their application in cell culture, protein expression, and modulation of cellular responses.

"Drug discovery & development segment accounted for the largest share of the application segment in 2022."

Based on application, the recombinant proteins market is segmented into, drug discovery and development, biopharmaceutical production, research, diagnostics, and other applications. In 2022, the drug discovery and development segment accounted for the largest share of the recombinant proteins market. The segment held the largest share in the market due to application of recombinant proteins in developing biopharmaceuticals and understanding the functions of potential drug targets.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

"Asia Pacific region is likely to grow at a faster pace in the recombinant proteins market."

The recombinant proteins market region is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and the Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by increasing demand for protein based drugs, rising government funding for recombinant proteins production and development of biotechnology-based drugs.

The primary interviews conducted for this report can be categorized as follows:

-□By Respondent: Supply Side- 70%, and Demand Side - 30%

-□By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%

-□By Region: North America: 40%, Europe: 25%, Asia Pacific: 20%, Latin America: 10%, and the Middle East and Africa: 5%

List of Companies Profiled in the Report:

-□Bio-Techne (US)

-□Thermo Fisher Scientific Inc. (US)

-□Merck KGaA (Germany)

-□Abcam plc (UK)

-□Abnova Corporation (Taiwan)

-□Biolegend Inc (US)

-□Bio-Rad Laboratories Inc. (US)

-□BPS Bioscienc Inc (US)

-□Enzo Biochem, Inc. (US)

-□GenScript (China)

-□Miltenyi Biotec B.V. & Co. KG (Germany)

-□Proteintech Group, Inc. (US)

-□Sino Biological Inc. (China)

-□ACROBiosystems Group (US)

-□Aviva Systems Biology Corporation (US)

-□Sartorius CellGenix GmbH (Germany)

-□Icosagen (Estonia)

-□Neuromics (US)

-□ProSpec-Tany Technogene Ltd. (Israel)

-□ProteoGenix S.A.S (France)

-□RayBiotech Inc (US)

-□Laurus Bio (India)

-□Stemcell Technologies (Canada)

-□StressMarq Biosciences Inc. (Canada)

-□United States Biological (US)

Research Coverage:

This report provides a detailed picture of the recombinant proteins market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end-user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall recombinant proteins market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

-□Analysis of key drivers (rising incidence of chronic diseases, unleashing innovation in biologics and biosimilars with patent expiry, increasing government support for R&D in life sciences, growing preference for personalized medicine), restraints (high production costs, stringent regulatory approval processes), opportunities (advancements in gene editing technologies, high growth potential of emerging markets, emergence of novel expression systems) and challenges (challenges associated with delivery systems) are influencing the growth of recombinant proteins market.

-□Product Development/Innovation: Detailed insights on newly launched products of the recombinant proteins market.

-□Market Development: Comprehensive information about lucrative markets - the report analyses the recombinant proteins market across varied regions.

-□Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the recombinant proteins market.

-□Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Bio-Techne (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Abcam plc (UK), Abnova Corporation (Taiwan), Biologend Inc (US), Bio-Rad Laboratories Inc. (US), BPS Bioscienc Inc (US), Enzo Biochem Inc. (US) and GenScript (China).

## **Table of Contents:**

1	INTRODUCTION	33
1.1	STUDY OBJECTIVES	33
1.2	MARKET DEFINITION	33
1.2.1	INCLUSIONS AND EXCLUSIONS	33
1.3	MARKET SCOPE	34
1.3.1	MARKETS COVERED	34
1.3.2	YEARS CONSIDERED	35
1.3.3	CURRENCY CONSIDERED	35
1.4	RESEARCH LIMITATIONS	35
1.5	STAKEHOLDERS	36
1.6	SUMMARY OF CHANGES	36
1.7	RECESSION IMPACT	37
2	RESEARCH METHODOLOGY	38
2.1	RESEARCH DATA	38
FIGURE 1	RESEARCH DESIGN	38
2.1.1	SECONDARY DATA	39
2.1.2	PRIMARY DATA	40
FIGURE 2	RECOMBINANT PROTEINS MARKET: BREAKDOWN OF PRIMARIES	40
2.2	MARKET SIZE ESTIMATION	41
FIGURE 3	MARKET SIZE ESTIMATION: SUPPLY SIDE ANALYSIS (2022)	41
FIGURE 4	MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022	42
FIGURE 5	ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2022)	42
2.2.1	INSIGHTS FROM PRIMARIES	44
FIGURE 6	MARKET VALIDATION FROM PRIMARY EXPERTS	44
2.2.2	SEGMENT ASSESSMENT (BY PRODUCT, APPLICATION, HOST CELL, AND END USER)	44
FIGURE 7	MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH	44
2.3	GROWTH RATE ASSUMPTIONS	45
FIGURE 8	RECOMBINANT PROTEINS MARKET: CAGR PROJECTIONS (2023-2028)	46
FIGURE 9	RECOMBINANT PROTEINS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES	46

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.4	MARKET BREAKDOWN AND DATA TRIANGULATION	47
	FIGURE 10 DATA TRIANGULATION METHODOLOGY	47
2.5	STUDY ASSUMPTIONS	48
2.6	RISK ANALYSIS	48
2.7	RECESSION IMPACT ANALYSIS	48
	TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024-2028 (% GROWTH)	49
	TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)	49
	TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)	49
3	EXECUTIVE SUMMARY	50
	FIGURE 11 RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)	50
	FIGURE 12 RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)	51
	FIGURE 13 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2023 VS. 2028 (USD MILLION)	51
	FIGURE 14 RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2023 VS. 2028 (USD MILLION)	52
	FIGURE 15 RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2023 VS. 2028 (USD MILLION)	53
	FIGURE 16 RECOMBINANT PROTEINS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)	54
	FIGURE 17 GEOGRAPHICAL SNAPSHOT OF RECOMBINANT PROTEINS MARKET	55
4	PREMIUM INSIGHTS	56
4.1	RECOMBINANT PROTEINS MARKET OVERVIEW	56
	FIGURE 18 INCREASING GOVERNMENT SUPPORT FOR R&D IN LIFE SCIENCES TO DRIVE MARKET	56
4.2	NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT (2022)	57
	FIGURE 19 GROWTH FACTORS & CHEMOKINES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022	57
4.3	RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2023 VS. 2028	58
	FIGURE 20 GROWTH FACTORS & CHEMOKINES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD	58
4.4	RECOMBINANT PROTEINS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	58
	FIGURE 21 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD	58
5	MARKET OVERVIEW	59
5.1	INTRODUCTION	59
5.2	MARKET DYNAMICS	59
	FIGURE 22 RECOMBINANT PROTEINS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	59
	TABLE 4 RECOMBINANT PROTEINS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	60
5.2.1	DRIVERS	60
5.2.1.1	Rising incidence of chronic diseases	60
	FIGURE 23 NUMBER OF CANCER CASES IN US (2017 - 2022)	61
5.2.1.2	Increasing demand for biologics and biosimilars due to patent expiry	62
5.2.1.3	Increasing government support for R&D in life sciences	63
	TABLE 5 GOVERNMENT FUNDING FOR LIFE SCIENCE RESEARCH (2022)	63
5.2.1.4	Growing preference for personalized medicine	64
5.2.2	RESTRAINTS	64
5.2.2.1	High production costs	64
5.2.2.2	Stringent regulatory approval processes	65
5.2.3	OPPORTUNITIES	66
5.2.3.1	Advancements in gene editing technologies	66
5.2.3.2	High growth potential of emerging markets	67
5.2.3.3	Emergence of novel expression systems	68
5.2.4	CHALLENGES	69
5.2.4.1	Challenges associated with delivery systems	69
5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	69

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 24 REVENUE SHIFTS AND NEW REVENUE POCKETS FOR RECOMBINANT PROTEIN MANUFACTURERS 69

5.4 PRICING ANALYSIS 70

5.4.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYERS 70

TABLE 6 RECOMBINANT PROTEIN PRODUCTS 70

5.4.2 AVERAGE SELLING PRICE TREND OF RECOMBINANT PROTEINS 74

5.5 TECHNOLOGY ANALYSIS 74

5.6 VALUE CHAIN ANALYSIS 75

FIGURE 25 VALUE CHAIN ANALYSIS: MANUFACTURING & ASSEMBLY PHASE CONTRIBUTES MAXIMUM VALUE TO VALUE CHAIN OF RECOMBINANT PROTEINS 76

5.7 ECOSYSTEM MARKET/MAP 77

FIGURE 26 ECOSYSTEM MARKET/MAP 77

TABLE 7 RECOMBINANT PROTEINS MARKET: ROLE IN ECOSYSTEM: 77

5.8 REGULATORY ANALYSIS 79

TABLE 8 KEY REGULATORY AGENCIES 79

5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81

TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81

TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82

TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83

TABLE 12 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83

TABLE 13 MIDDLE EAST: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84

TABLE 14 AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84

5.9 PORTER'S FIVE FORCES ANALYSIS 85

TABLE 15 RECOMBINANT PROTEINS MARKET: PORTER'S FIVE FORCES ANALYSIS 85

5.9.1 THREAT OF NEW ENTRANTS 85

5.9.2 THREAT OF SUBSTITUTES 85

5.9.3 BARGAINING POWER OF SUPPLIERS 86

5.9.4 BARGAINING POWER OF BUYERS 86

5.9.5 INTENSITY OF COMPETITIVE RIVALRY 86

5.10 PATENT ANALYSIS 87

FIGURE 27 PATENT APPLICATIONS FOR RECOMBINANT PROTEINS, DECEMBER 2013-DECEMBER 2023 87

TABLE 16 RECOMBINANT PROTEINS MARKET: INDICATIVE LIST OF PATENTS 87

5.11 KEY CONFERENCES AND EVENTS 89

TABLE 17 DETAILED LIST OF KEY CONFERENCES AND EVENTS (2023-2024) 89

5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 90

5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 90

FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RECOMBINANT PROTEINS 90

5.12.2 BUYING CRITERIA FOR RECOMBINANT PROTEINS 91

FIGURE 29 KEY BUYING CRITERIA FOR END USERS 91

6 RECOMBINANT PROTEINS MARKET, BY PRODUCT 92

6.1 INTRODUCTION 93

TABLE 18 RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 93

6.2 GROWTH FACTORS & CHEMOKINES 93

TABLE 19 RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY REGION, 2021-2028 (USD MILLION) 95

TABLE 20 RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION) 95

TABLE 21 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION) 96

TABLE 22 EUROPE: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

MILLION) 96

TABLE 23 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION) 97

TABLE 24 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION) 97

TABLE 25 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, COUNTRY, 2021-2028 (USD MILLION) 98

6.2.1 INTERFERONS (IFNS) 98

6.2.1.1 Ability to regulate critical cellular processes across research applications to propel market 98

TABLE 26 RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY REGION, 2021-2028 (USD MILLION) 99

TABLE 27 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021-2028 (USD MILLION) 100

TABLE 28 EUROPE: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021-2028 (USD MILLION) 100

TABLE 29 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021-2028 (USD MILLION) 101

TABLE 30 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021-2028 (USD MILLION) 101

TABLE 31 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021-2028 (USD MILLION) 102

6.2.2 INTERLEUKINS (ILS) 102

6.2.2.1 Rising focus on personalized therapeutics to drive market 102

TABLE 32 RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY REGION, 2021-2028 (USD MILLION) 103

TABLE 33 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021-2028 (USD MILLION) 103

TABLE 34 EUROPE: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021-2028 (USD MILLION) 104

TABLE 35 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021-2028 (USD MILLION) 104

TABLE 36 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021-2028 (USD MILLION) 105

TABLE 37 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021-2028 (USD MILLION) 105

6.2.3 OTHER GROWTH FACTORS & CHEMOKINES 105

TABLE 38 RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY REGION, 2021-2028 (USD MILLION) 106

TABLE 39 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION) 106

TABLE 40 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION) 107

TABLE 41 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION) 107

TABLE 42 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION) 108

TABLE 43 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION) 108

6.3 IMMUNE RESPONSE PROTEINS 109

6.3.1 HIGH UTILIZATION OF IMMUNE CHECKPOINT PROTEINS IN CANCER IMMUNOTHERAPY TO PROPEL MARKET 109

TABLE 44 RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY REGION, 2021-2028 (USD MILLION) 109

TABLE 45 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 110

TABLE 46 EUROPE: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 110

TABLE 47 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 111

TABLE 48 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 111

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 49 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 112

6.4 STRUCTURAL PROTEINS 112

6.4.1 ATTACHMENT FACTORS IN CELL CULTURE APPLICATIONS TO DRIVE MARKET 112

TABLE 50 RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY REGION, 2021-2028 (USD MILLION) 113

TABLE 51 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 114

TABLE 52 EUROPE: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 114

TABLE 53 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 115

TABLE 54 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 115

TABLE 55 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 116

6.5 MEMBRANE PROTEINS 116

6.5.1 ESSENTIAL PROCESS REGULATION OF STRUCTURAL CELLS TO SUPPORT MARKET GROWTH 116

TABLE 56 RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY REGION, 2021-2028 (USD MILLION) 117

TABLE 57 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 117

TABLE 58 EUROPE: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 118

TABLE 59 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 118

TABLE 60 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 119

TABLE 61 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 119

6.6 KINASE PROTEINS 119

6.6.1 ACTIVE METABOLIZATION OF LIPIDS AND NUCLEOTIDES TO DRIVE MARKET 119

TABLE 62 RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY REGION, 2021-2028 (USD MILLION) 120

TABLE 63 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 120

TABLE 64 EUROPE: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 121

TABLE 65 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 121

TABLE 66 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 122

TABLE 67 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 122

6.7 REGULATORY PROTEINS 122

6.7.1 ABILITY TO MODULATE CELLULAR PROCESSES TO DRIVE MARKET 122

TABLE 68 RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY REGION, 2021-2028 (USD MILLION) 123

TABLE 69 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 123

TABLE 70 RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION) 124

TABLE 71 EUROPE: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 124

TABLE 72 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 125

TABLE 73 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 125

6.8 RECOMBINANT METABOLIC ENZYMES 126

6.8.1 HIGH ADOPTION IN BIOTECHNOLOGICAL APPLICATIONS FOR THERAPEUTIC DEVELOPMENT TO BOOST DEMAND 126

TABLE 74 RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY REGION, 2021-2028 (USD MILLION) 126

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 75 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021-2028 (USD MILLION) 127

TABLE 76 EUROPE: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021-2028 (USD MILLION) 127

TABLE 77 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021-2028 (USD MILLION) 128

TABLE 78 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021-2028 (USD MILLION) 128

TABLE 79 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021-2028 (USD MILLION) 129

6.9 ADHESION MOLECULES & RECEPTORS 129

6.9.1 ENHANCED FACILITATION OF EXTRACELLULAR MATRIX INTERACTIONS TO SUPPORT MARKET GROWTH 129

TABLE 80 RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY REGION, 2021-2028 (USD MILLION) 130

TABLE 81 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021-2028 (USD MILLION) 130

TABLE 82 EUROPE: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021-2028 (USD MILLION) 131

TABLE 83 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021-2028 (USD MILLION) 131

TABLE 84 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021-2028 (USD MILLION) 132

TABLE 85 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021-2028 (USD MILLION) 132

6.10 OTHER RECOMBINANT PROTEINS 132

TABLE 86 RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY REGION, 2021-2028 (USD MILLION) 133

TABLE 87 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 133

TABLE 88 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 134

TABLE 89 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 134

TABLE 90 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 135

TABLE 91 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 135

?

7 RECOMBINANT PROTEINS MARKET, BY APPLICATION 136

7.1 INTRODUCTION 137

TABLE 92 RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 137

7.2 DRUG DISCOVERY & DEVELOPMENT 137

TABLE 93 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION) 138

TABLE 94 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2021-2028 (USD MILLION) 138

TABLE 95 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION) 139

TABLE 96 EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION) 139

TABLE 97 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

(USD MILLION) 140

TABLE 98 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028

(USD MILLION) 140

TABLE 99 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028

(USD MILLION) 141

7.2.1 BIOLOGICS 141

7.2.1.1 High adoption in autoimmune disease & cancer treatment to propel market 141

TABLE 100 RECOMBINANT PROTEINS MARKET: KEY BIOLOGICS AND INDICATIONS 141

TABLE 101 RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY REGION, 2021-2028 (USD MILLION) 142

TABLE 102 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION) 142

TABLE 103 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION) 143

TABLE 104 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION) 143

TABLE 105 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION) 144

TABLE 106 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION) 144

7.2.2 VACCINES 144

7.2.2.1 Rising incidence of infectious diseases to boost demand 144

TABLE 107 RECOMBINANT PROTEINS MARKET FOR VACCINES, BY REGION, 2021-2028 (USD MILLION) 145

TABLE 108 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION) 145

TABLE 109 EUROPE: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION) 146

TABLE 110 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION) 146

TABLE 111 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION) 147

TABLE 112 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION) 147

7.2.3 CELL & GENE THERAPY 147

7.2.3.1 Growing focus on CAR-T therapies to propel market 147

TABLE 113 RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY REGION, 2021-2028 (USD MILLION) 148

TABLE 114 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) 149

TABLE 115 EUROPE: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) 149

TABLE 116 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) 150

TABLE 117 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) 150

TABLE 118 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) 151

7.3 RESEARCH 151

TABLE 119 RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION) 152

TABLE 120 RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY REGION, 2021-2028 (USD MILLION) 152

TABLE 121 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) 152

TABLE 122 EUROPE: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) 153

TABLE 123 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) 153

TABLE 124 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) 154

TABLE 125 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) 154

7.3.1 ACADEMIC RESEARCH 154

7.3.1.1 Wide application in molecular & gene expression studies to propel market 154

TABLE 126 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY REGION, 2021-2028 (USD MILLION) 155

TABLE 127 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) 155

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 128 □ EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY COUNTRY, 2021-2028 (USD MILLION) □ 156

TABLE 129 □ ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) □ 156

TABLE 130 □ LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) □ 157

TABLE 131 □ MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) □ 157

7.3.2 □ BIOTECHNOLOGY RESEARCH □ 157

7.3.2.1 □ Growing focus on bioengineering and genomics to fuel market □ 157

TABLE 132 □ RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY REGION, 2021-2028 (USD MILLION) □ 158

TABLE 133 □ NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) □ 159

TABLE 134 □ EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) □ 159

TABLE 135 □ ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) □ 160

TABLE 136 □ LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) □ 160

TABLE 137 □ MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) □ 161

7.4 □ BIOPHARMACEUTICAL PRODUCTION □ 161

7.4.1 □ INCREASING DEVELOPMENT OF PROTEIN-BASED DRUGS TO SUPPORT MARKET GROWTH □ 161

TABLE 138 □ RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2021-2028 (USD MILLION) □ 162

TABLE 139 □ NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION) □ 162

TABLE 140 □ EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION) □ 163

TABLE 141 □ ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION) □ 163

TABLE 142 □ LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION) □ 164

TABLE 143 □ MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION) □ 164

7.5 □ DIAGNOSTICS □ 164

7.5.1 □ GROWING FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET □ 164

TABLE 144 □ RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION) □ 165

TABLE 145 □ NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION) □ 165

TABLE 146 □ EUROPE: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION) □ 166

TABLE 147 □ ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION) □ 166

TABLE 148 □ LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION) □ 167

TABLE 149 □ MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION) □ 167

7.6 □ OTHER APPLICATIONS □ 167

TABLE 150 □ RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) □ 168

TABLE 151 □ NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) □ 168

TABLE 152 □ EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) □ 169

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 153	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	169
TABLE 154	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	170
TABLE 155	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	170
8	RECOMBINANT PROTEINS MARKET, BY HOST CELL	171
8.1	INTRODUCTION	172
TABLE 156	RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)	172
8.2	MAMMALIAN SYSTEMS	172
8.2.1	HIGH UPTAKE IN BIOTECHNOLOGY APPLICATIONS TO PROPEL MARKET	172
TABLE 157	RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY REGION, 2021-2028 (USD MILLION)	173
TABLE 158	NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)	173
TABLE 159	EUROPE: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)	174
TABLE 160	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)	174
TABLE 161	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)	175
TABLE 162	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)	175
8.3	INSECT CELLS	175
8.3.1	COST-EFFICIENT AND HIGH-YIELD CHARACTERISTICS TO DRIVE MARKET	175
TABLE 163	RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY REGION, 2021-2028 (USD MILLION)	176
TABLE 164	NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	177
TABLE 165	EUROPE: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	177
TABLE 166	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	178
TABLE 167	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	178
TABLE 168	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	179
8.4	YEAST & FUNGI	179
8.4.1	NEW APPLICATIONS IN VACCINE DEVELOPMENT AND DIABETES TREATMENT TO BOOST DEMAND	179
TABLE 169	RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY REGION, 2021-2028 (USD MILLION)	180
TABLE 170	RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021-2028 (USD MILLION)	180
TABLE 171	RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021-2028 (USD MILLION)	181
TABLE 172	RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021-2028 (USD MILLION)	181
TABLE 173	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021-2028 (USD MILLION)	182
TABLE 174	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021-2028 (USD MILLION)	182
8.5	BACTERIAL CELLS	182
8.5.1	SIMPLIFIED GENETIC MANIPULATION AND SCALABILITY ADVANTAGES TO DRIVE MARKET	182
TABLE 175	RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY REGION, 2021-2028 (USD MILLION)	183
TABLE 176	RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	184
TABLE 177	RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	184
TABLE 178	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	185
TABLE 179	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	185
TABLE 180	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	185
8.6	OTHER HOST CELLS	186
TABLE 181	RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY REGION, 2021-2028 (USD MILLION)	186

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 182 □ NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021-2028 (USD MILLION) □ 187

TABLE 183 □ EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021-2028 (USD MILLION) □ 187

TABLE 184 □ ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021-2028 (USD MILLION) □ 188

TABLE 185 □ LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021-2028 (USD MILLION) □ 188

TABLE 186 □ MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021-2028 (USD MILLION) □ 189

9 □ RECOMBINANT PROTEINS MARKET, BY END USER □ 190

9.1 □ INTRODUCTION □ 191

TABLE 187 □ RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION) □ 191

9.2 □ PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES □ 191

9.2.1 □ RISING DEVELOPMENT OF GENE THERAPIES AND VACCINES TO PROPEL MARKET □ 191

TABLE 188 □ RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2021-2028 (USD MILLION) □ 193

TABLE 189 □ NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) □ 193

TABLE 190 □ EUROPE: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) □ 194

TABLE 191 □ ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) □ 194

TABLE 192 □ LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) □ 195

TABLE 193 □ MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) □ 195

9.3 □ BIOTECHNOLOGY COMPANIES □ 195

9.3.1 □ RISING NUMBER OF PROTEIN-BASED RESEARCH PROJECTS TO BOOST DEMAND □ 195

TABLE 194 □ RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION) □ 196

TABLE 195 □ NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) □ 196

TABLE 196 □ EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) □ 197

TABLE 197 □ ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) □ 197

TABLE 198 □ LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) □ 198

TABLE 199 □ MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) □ 198

9.4 □ ACADEMIC & RESEARCH INSTITUTES □ 199

9.4.1 □ FAVORABLE GOVERNMENT INVESTMENTS TO PROPEL MARKET □ 199

TABLE 200 □ RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION) □ 200

TABLE 201 □ NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) □ 200

TABLE 202 □ EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) □ 201

TABLE 203 □ ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) □ 201

TABLE 204 □ LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021-2028

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

(USD MILLION) 202

TABLE 205 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021-2028

(USD MILLION) 202

9.5 CONTRACT RESEARCH ORGANIZATIONS 202

9.5.1 RISING OUTSOURCING OF CLINICAL TRIAL SERVICES TO SUPPORT MARKET GROWTH 202

TABLE 206 RECOMBINANT PROTEINS MARKET FOR CROS, BY REGION, 2021-2028 (USD MILLION) 203

TABLE 207 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021-2028 (USD MILLION) 203

TABLE 208 EUROPE: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021-2028 (USD MILLION) 204

TABLE 209 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021-2028 (USD MILLION) 204

TABLE 210 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021-2028 (USD MILLION) 205

TABLE 211 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021-2028 (USD MILLION) 205

9.6 OTHER END USERS 205

TABLE 212 RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION) 206

TABLE 213 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION) 206

TABLE 214 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION) 207

TABLE 215 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION) 207

TABLE 216 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION) 208

TABLE 217 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION) 208

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development (Biologics, Vaccines, Cell & Gene Therapy), Research, Biopharma Production) & Region - Global Forecast to 2028**

Market Report | 2024-02-05 | 408 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Zip Code\*

Country\*

Date

2026-03-05

Signature

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)